Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Carcinoma, Non-Small-Cell Lung
Brief summary
Observational, retrospective cohort study that will include patients diagnosed with NSCLC and ALK rearrangement between January 2015 and December 2020.
Interventions
None listed
Sponsors
Latin American Cooperative Oncology Group
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients older than 18 years; * Newly diagnosed advanced stage IIIB-IV NSCLC (AJCC 8th edition) or locally advance/distant relapse in the period of January 2015 to December 2020. * NSCLC with pathological confirmation of ALK rearrangement by immunohistochemistry, fluorescent in situ hybridization (FISH) or next generation sequencing (NGS); * ECOG 0-4; * Patients with CNS metastases are also considered eligible, regardless of the initial treatment instituted.
Exclusion criteria
\- Incomplete medical chart in terms of date of diagnosis, ALK test results and outcomes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Describe the treatment sequencing of ALK positive advanced NSCLC in a real-world setting. | December of 2020 |
| - Describe the timelines from the appearance of symptoms, histopathological diagnosis, application of the molecular test, and start of treatment. | December of 2020 |
Secondary
| Measure | Time frame |
|---|---|
| - Estimate the progression-free survival of first-line treatment, and other subsequent lines; | December of 2020 |
Other
| Measure | Time frame |
|---|---|
| - Estimate the overall survival from diagnosis | December of 2020 |
| - Compare patients' outcomes among baseline characteristics defined subgroups; | December of 2020 |
| - Evaluate health economics parameters in the context. | December of 2020 |
Countries
Brazil
Outcome results
None listed